This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundInstant atrialfibrillation termination (AFT) during radiofrequency ablation has been suggested as a predictor of prognosis in persistent atrialfibrillation (AF). However, its role in cryoballoon ablation remains unclear. years] were included. During a follow-up of 16.0
Atrialfibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. It can be associated with reduced quality of life and complications such as heart failure and stroke. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control.
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrialfibrillationablation, Musat et al. ERAT is often attributed to transient inflammation induced by tissue damage during ablation and short-term imbalances in autonomic innervation.
(MedPage Today) -- For patients undergoing catheter ablation for atrialfibrillation (Afib), there was no signal that a brief course of colchicine reduced atrialarrhythmia recurrence or improved clinical outcomes when taken for 10 days starting.
An international consensus statement on how to treat atrialfibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.
BackgroundAtrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, posing significant health burdens. Pulsed field ablation (PFA) is an emerging non-thermal technique that is gaining traction due to the ability to selectively target myocardial cells and minimize damage to surrounding tissues.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF).
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.
(MedPage Today) -- BOSTON -- For persistent atrialfibrillation (Afib), adding artificial intelligence guidance for ablation site selection improved success, the TAILORED trial showed. Freedom from Afib after one procedure regardless of antiarrhythmic.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 1,ii For patients who had received ablation, median procedure and fluoroscopy times were 90.0 Food & Drug Administration ( FDA ).
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability. The company has obtained U.S.
tim.hodson Wed, 03/12/2025 - 15:36 Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrialfibrillation (A-Fib). This innovative treatment represents a significant advancement over traditional thermal ablation methods and provides a more effective solution for patients.
IntroductionAtrial fibrillation (AF) is a prevalent cardiac arrhythmia and a significant contributor to cardioembolic stroke, a condition closely linked to cognitive decline. However, research reveals that AF itself is independently associated with an increased risk of cognitive impairment.
Introduction Catheter ablation is an effective and safe strategy for treating atrialfibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n = 27) had persistent atrialfibrillation.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
When atrialfibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.
Typical atrial flutter commonly occurs in patients with atrialfibrillation (AF). Limited information exists regarding the effects of concurrent atrial flutter on the long-term outcomes of rhythm control. The data were obtained from a multicenter registry of cryoballoon ablation for AF ( n = 2,689).
Background Cryoballoon ablation (CBA) and laser balloon ablation (LBA) are two innovative ways for the treatment of atrialfibrillation (AF). This study aimed to evaluate the efficacy and safety of cryoballoon ablation and laser balloon ablation in patients with AF.
In this weeks View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrialfibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis.
Background Catheter ablation (CA) for symptomatic atrialfibrillation (AF) offers the best outcomes for patients. Data were collected from the MPH AF Ablation Registry with the approval of the institutional research board. 11.4), and left atrial width as measured on CT in the upper quartile ( p = 0.04, HR: 2.5,
Backgroundwide antral pulmonary vein isolation (PVI) is effective for treating paroxysmal atrialfibrillation (PAF), although time-demanding. Procedural data and electrophysiology (EP) laboratory times were systematically collected and analyzed.
Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrialarrhythmia recurrence in patients with symptomatic paroxysmal atrialfibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.
Overview of the study population and effects observed after catheter ablation for atrialfibrillation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. to 39.18.3% ( p <0.001) following ablation. interquartile range 13.663.3)
Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrialfibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The rate of 12-month freedom from clinical atrialarrhythmia recurrence was 85.1%
Abstract Background and Aims Atrialfibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable treatment option for selected patients. However, its safety profile in liver cirrhosis (LC) populations remains underexplored.
Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.
Early recurrence of atrial tachyarrhythmia (ERAT) is common following catheter ablation of atrialfibrillation (AF). The specific clinical and arrhythmia characteristics of ERAT influencing late recurrence risk in persistent AF is unclear.
Acutely effective repeat radiofrequency catheter ablation (RFCA) after previous atrialfibrillationablation depends on several parameters including local impedance (LI), contact force (CF) and power.
A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrialfibrillation (AF) is still reported.1 A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrialfibrillation (AF) is still reported.1
Atrialfibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
Introduction Pulsed-field ablation (PFA) is a novel modality for pulmonary vein isolation in patients with atrialfibrillation (AF). first-time AF ablation. first-time AF ablation. In first-time ablation cases, acute isolation of all pulmonary veins was achieved in 99.5% The patients were 32.1% of patients.
milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrialfibrillation (AFib).
Catheter ablation of atrialfibrillation in infiltrative cardiomyopathies ABSTRACT Atrial and ventricular arrhythmias are common in patients with Infiltrative heart diseases. AF is the most common arrhythmia identified in patients with amyloidosis due to cellular infiltration and atrial dilation.
Early recurrence of atrialarrhythmia (ERA) is commonly seen following catheter ablation of atrialfibrillation (AF), with reported incidences of up to 61% in the first three months.1
ABSTRACT Introduction Atrialfibrillation (AF) is the most common arrhythmia, and atrioventricular (AV) node ablation with pacemaker implantation is a therapeutic option for refractory cases. However, AV node ablation in patients with bioprosthetic tricuspid valves poses technical challenges.
Atrialfibrillation (AF) and premature ventricular complexes (PVCs) are common arrhythmias associated with significant morbidity and mortality.1,2 3 Catheter ablation is recommended for AF and PVCs in symptomatic, drug-refractory patients, but evidence for combined ablation is lacking.
Asthma is a known risk factor for atrialfibrillation (AF), the most common sustained arrhythmia. While radiofrequency catheter ablation is effective in treating AF, the impact of asthma and its severity on ablation outcomes has not been previously explored.
There is a limited knowledge on atrialarrhythmias recurring after complex left atrial (LA) pulsed field ablation (PFA) for longstanding persistent atrialfibrillation (LSPAF).
Atrialfibrillation (AF) catheter ablation trials report arrhythmia-free survival using different post-ablation rhythm monitoring protocols, resulting in difficulties in the interpretation of the recurrence rates and comparison of ablation strategies and technologies.
Atrialfibrillation (AF) is the most common cardiac arrhythmia. Catheter ablation (CA) has emerged as an important modality for managing AF, improving quality of life, and potentially reversing cardiac dysfunction.
Animal studies suggest that catheter ablation-associated parasympathetic and sympathetic denervation could result in increased ventricular arrhythmias (VA). The impact of catheter ablation of atrialfibrillation on VA burden in humans has not been assessed.
Atrialfibrillation (AF), a common cardiac arrhythmia, presents unique management challenges, particularly in patients with varying degrees of frailty. This study aims to elucidate the impact of frailty on readmission rates and the utilization of ablation therapy in AF patients.
Atrialfibrillation (AF) is the most common cardiac arrhythmia with increasing prevalence globally. Catheter ablation is well-established treatment for prevention of AF recurrences and decreasing AF symptoms.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content